This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Mizuho Securities Gives a Buy Rating to Alcon (ALC)
In a report released on April 13, Anthony Petrone from Mizuho Securities assigned a Buy rating to Alcon, with a price target of $95.00. The company’s shares closed yesterday at CHF61.70.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Petrone covers the Healthcare sector, focusing on stocks such as Pulse Biosciences, Lantheus, and Haemonetics. According to TipRanks, Petrone has an average return of 5.4% and a 47.33% success rate on recommended stocks.
In addition to Mizuho Securities, Alcon also received a Buy from RBC Capital’s Jack Reynolds-Clark in a report issued yesterday. However, on April 7, Stifel Nicolaus maintained a Hold rating on Alcon (NYSE: ALC).
ALC market cap is currently CHF30.83B and has a P/E ratio of 38.35.
Read More on ALC:
Disclaimer & DisclosureReport an Issue
- Alcon price target lowered to $87 from $92 at BTIG
- William Blair med tech analyst holds an analyst/industry conference call
- Alcon launches Clareon TruPlus at ASCRS 2026
- Alcon Sets April 30, 2026 AGM, Proposes New Director and CHF 0.28 Dividend
- Sight Sciences awarded monetary damages by district court against Alcon
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
